

Message

**From:** Maguire, Megan [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=6A013C79651D4A86AFD93DFC45128EBB-MAGUIRE, MEGAN]  
**Sent:** 2/6/2019 6:08:26 PM  
**To:** Hubbard, Carolyn [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2a93ce3245494318b109e87f7d826284-Hubbard, Carolyn]; Dunlap, David [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=591eb15a268249dda0c05a7451f765c3-Dunlap, Dav]  
**CC:** Orme-Zavaleta, Jennifer [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3c5a111dc377411595e5b24b5d96146b-Orme-Zavaleta, Jennifer]; Fitzpatrick, Kacey [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b91d7852b66540ff9f823f4c736927a1-Fitzpatrick]; Fitzmorris, Amanda [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4051a5cf28144ee599b7cb3e9c2527bf-Fitzmorris,]; D'Amico, Louis [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=78a91f83c4414910be286efe02004dbc-D'Amico, Louis J.]  
**Subject:** Re: ACTION: The Intercept re eTO and Dunlap

## Deliberative Process / Ex. 5

Megan

---

**From:** Hubbard, Carolyn  
**Sent:** Wednesday, February 6, 2019 9:30:31 AM  
**To:** Dunlap, David  
**Cc:** Orme-Zavaleta, Jennifer; Maguire, Megan; Fitzpatrick, Kacey; Fitzmorris, Amanda; D'Amico, Louis  
**Subject:** FW: ACTION: The Intercept re eTO and Dunlap

Hi David- please see the media inquiry below from Sharon Lerner with the Intercept.

**Deliberative Process / Ex. 5**

## Deliberative Process / Ex. 5

- 11) When did David Dunlap, the head of EPA's Office of Research and Development, begin work at the agency?
- 12) Mr. Dunlap recused himself from working on the IRIS assessment of formaldehyde in a letter dated December 19, 2018. That same day, IRIS issued an agenda for upcoming activities that omitted formaldehyde, which had been on previous agendas. The timing — and the fact that Dunlap's letter recused himself from future work on the chemical but didn't address any work he might have done up to that point — seems to suggest that he may have had a role in removing formaldehyde from IRIS's agenda. Do you wish to comment?
- 13) Last year, for the second time, representatives of the company Denka asked IRIS to reconsider its assessment of chloroprene. What is the status of that request?

---

**From:** Jones, Enesta  
**Sent:** Wednesday, February 6, 2019 9:21 AM  
**To:** Davis, Alison; Bremer, Kristen; DeLuca, Isabel; Maguire, Megan; Hubbard, Carolyn  
**Cc:** Jones, Enesta  
**Subject:** ACTION: The Intercept re eTO and Dunlap

## Deliberative Process / Ex. 5

Below are some questions related to a story I'm writing about air pollution. Can you please get back to me by the end of the day this coming Friday, 2/8?

1) A recent report by a CBS News affiliate in Chicago included allegations that the EPA has known Sterigenics was emitting ethylene oxide at unsafe levels for years. Do you want to respond to that or comment?

2) I note in my story that some in the Willowbrook area felt that the EPA didn't respond quickly enough to their ethylene oxide problem. I did see your October press release that address some of these criticisms. Just wanted to see if you wanted to add anything to that.

3) That press release notes that you requested that ATSDR evaluate the potential health impacts of the ethylene oxide emitted from the Sterigenics plant in Willowbrook. Did you ask ATSDR for reports for the other places where ethylene oxide is emitted at similar or higher levels?

If so, which ones?

If not, why not?

4) As soon as the NATA report was published in August of 2018, you notified the residents of Willowbrook about the risk they faced. Did you do this for any other community that had an elevated risk of cancer due to ethylene oxide or for any other community that had an elevated risk of cancer due to other tract pollutants?

If so, which ones and when?

If not, why not?

5) Did you create webpages about ethylene oxide contamination in places that were identified in the NATA report as having cancer risks above 100 in a million?

If so, which ones and when?

If not, why not?

6) The chief of the EPA's office of Air and Radiation, William Wehrum, went to speak with the residents of Willowbrook in November. Did Mr. Wehrum meet and speak with residents of any of the other communities with cancer risks from ethylene oxide that were above 100?

If so, which ones and when?

If not, why not?

7) Wilma Subra, an environmental consultant in Louisiana, said that the EPA has not asked ATSDR to evaluate the risk from ethylene oxide in communities in Louisiana that have an elevated risk of cancer or do air monitoring in those communities.

Is this true?

If not, in what other communities is EPA doing monitoring for ethylene oxide emissions? And for what other communities have they asked ATSDR to write reports on the threat from ethylene oxide emissions?

8) Besides the Sterigenics plant in Willowbrook, has the agency worked to help install pollution controls at any other facilities identified in the NATA report as responsible for ethylene oxide emissions that resulted in an estimated cancer risk above 100?

If so, which ones? And when?

If not, why not?

9) Did any EPA staff visit St. John to discuss the risk from chloroprene?

If so, who and when?

If not, why not?

10) The residents of St. John told me they didn't learn about the elevated cancer risk from chloroprene in their community until July of 2016 even though the NATA report identifying that risk was published in December of 2015. And when they learned of it, it was from an independent environmental consultant.

Why didn't you directly inform the residents of this risk as soon as you knew of it?

11) When did David Dunlap, the head of EPA's Office of Research and Development, begin work at the agency?

12) Mr. Dunlap recused himself from working on the IRIS assessment of formaldehyde in a letter that was dated December 19, 2018. That same day, IRIS issued an agenda for upcoming activities that omitted formaldehyde, which had been on previous agendas. The timing — and the fact that Dunlap's letter recused himself from

future work on the chemical but didn't address any work he might have done up to that point — seems to suggest that he may have had a role in removing formaldehyde from IRIS's agenda. Do you wish to comment?

13) Last year, for the second time, representatives of the company Denka asked IRIS to reconsider its assessment of chloroprene. What is the status of that request?

Thank you for your help and please let me know if you need clarification from me on any of this,  
Sharon

**Sharon Lerner**

**Reporter**

**The Intercept**

**mobile/signal** **Ex. 6**

**@fastlerner**

Click here (and scroll down) to read recent stories:

<https://theintercept.com/staff/sharon-lerner/>

Subscribe @ <http://sharonlerner.com/>

PGP:

CB29 D9FF 9285 3205 087E 83A1 0C30 2F39 4F30 8BFE